Application of heparin as a dual agent with antimalarial and liposome targeting activities toward Plasmodium-infected red blood cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 8, 2014, Pages 1719-1728

  Marques, Joana ^a,b   Moles, Ernest ^a,b   Urbán, Patricia ^a,b   Prohens, Rafel ^b   Busquets, Maria Antònia ^b   Sevrin, Chantal ^c   Grandfils, Christian ^c   Fernàndez Busquets, Xavier ^a,b  

^a INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Heparin; Liposomes; Malaria; Plasmodium; Targeted drug delivery

Indexed keywords

AMINES; BINDING ENERGY; BLOOD; CELL CULTURE; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; LIPOSOMES; POLYSACCHARIDES;

CONFOCAL FLUORESCENCE; DRUG DELIVERY STRATEGIES; DRUG LOADED NANOPARTICLE; HEPARIN; INTRACELLULAR PARASITES; MALARIA; PLASMODIUM; PLASMODIUM FALCIPARUM;

TARGETED DRUG DELIVERY;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; FLUORESCEIN; HEPARIN; LIPOSOME; NANOPARTICLE; PRIMAQUINE; ANTIMALARIAL AGENT;

ADSORPTION; ANIMAL EXPERIMENT; ANTICOAGULATION; ANTIMALARIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG TARGETING; ENCAPSULATION; ERYTHROCYTE; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; TRANSMISSION ELECTRON MICROSCOPY; CELL CULTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; PARASITOLOGY; PATHOGENICITY;

ANTIMALARIALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; HEPARIN; HUMANS; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; PLASMODIUM FALCIPARUM;

EID: 84908599826     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.06.002     Document Type: Article

References (50)

1. World Health Organization World Malaria Report 2013.
2. Tuteja R. Malaria - an overview. FEBS J 2007, 274(18):4670-4679.
3. Griffith K.S., Lewis L.S., Mali S., Parise M.E. Treatment of malaria in the United States: a systematic review. JAMA 2007, 297(20):2264-2277.
4. Daily J.P. Antimalarial drug therapy: the role of parasite biology and drug resistance. J Clin Pharmacol 2006, 46(12):1487-1497.
5. Fidock D.A., Rosenthal P.J., Croft S.L., Brun R., Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov 2004, 3(6):509-520.
6. Kappe S.H., Vaughan A.M., Boddey J.A., Cowman A.F. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010, 328(5980):862-866.
7. Murambiwa P., Masola B., Govender T., Mukaratirwa S., Musabayane C.T. Anti-malarial drug formulations and novel delivery systems: a review. Acta Trop 2011, 118(2):71-79.
8. Urbán P., Estelrich J., Cortés A., Fernàndez-Busquets X. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. J Control Release 2011, 151(2):202-211.
9. Beeson J.G., Andrews K.T., Boyle M., Duffy M.F., Choong E.K., Byrne T.J., et al. Structural basis for binding of Plasmodium falciparum erythrocyte membrane protein 1 to chondroitin sulfate and placental tissue and the influence of protein polymorphisms on binding specificity. J Biol Chem 2007, 282(31):22426-22436.
10. 1-varO, the rosetting domain of PfEMP1 from the VarO line of Plasmodium falciparum. Mol Biochem Parasitol 2010, 170(2):84-92.
11. Boyle M.J., Richards J.S., Gilson P.R., Chai W., Beeson J.G. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood 2010, 115(22):4559-4568.
12. Sheehy T.W., Reba R.C. Complications of falciparum malaria and their treatment. Ann Intern Med 1967, 66(4):807-809.
13. Smitskamp H., Wolthuis F.H. New concepts in treatment of malignant tertian malaria with cerebral involvement. BMJ 1971, 1:714-716.
14. Jaroonvesama N. Intravascular coagulation in falciparum malaria. Lancet 1972, 1:221-223.
15. Munir M., Tjandra H., Rampengan T.H., Mustadjab I., Wulur F.H. Heparin in the treatment of cerebral malaria. Paediatr Indones 1980, 20:47-50.
16. Rampengan T.H. Cerebral malaria in children. Comparative study between heparin, dexamethasone and placebo. Paediatr Indones 1991, 31:59-66.
17. World Health Organization Malaria Action Programme Severe and complicated malaria. Trans R Soc Trop Med Hyg 1986, 80(Suppl.):3-50.
18. Marchisio M.A., Tongo T., Ferruti P. A selective de-heparinizer filter made of new cross-linked polymers of a poly-amido-amine structure. Experientia 1973, 1(29):93-95.
19. Valle-Delgado J.J., Urbán P., Fernàndez-Busquets X. Demonstration of specific binding of heparin to Plasmodium falciparum-infected vs. non-infected red blood cells by single-molecule force spectroscopy. Nanoscale 2013, 5(9):3673-3680.
20. Hinterdorfer P., Baumgartner W., Gruber H.J., Schilcher K., Schindler H. Detection and localization of individual antibody-antigen recognition events by atomic force microscopy. Proc Natl Acad Sci U S A 1996, 93(8):3477-3481.
21. Kienberger F., Kada G., Mueller H., Hinterdorfer P. Single molecule studies of antibody-antigen interaction strength versus intra-molecular antigen stability. J Mol Biol 2005, 347(3):597-606.
22. Morfill J., Blank K., Zahnd C., Luginbühl B., Kühner F., Gottschalk K.-E., et al. Affinity-matured recombinant antibody fragments analyzed by single-molecule force spectroscopy. Biophys J 2007, 93(10):3583-3590.
23. Fernàndez-Busquets X. Heparin-functionalized nanocapsules: enabling targeted delivery of antimalarial drugs. Future Med Chem 2013, 5(7):737-739.
24. MacDonald R.C., MacDonald R.I., Menco B.P., Takeshita K., Subbarao N.K., Hu L.R. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1991, 1061(2):297-303.
25. Frazier S.B., Roodhouse K.A., Hourcade D.E., Zhang L. The quantification of glycosaminoglycans: a comparison of HPLC, carbazole, and Alcian Blue methods. Open Glycosci 2008, 1:31-39.
26. Cranmer S.L., Magowan C., Liang J., Coppel R.L., Cooke B.M. An alternative to serum for cultivation of Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 1997, 91(3):363-365.
27. Lambros C., Vanderberg J.P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 1979, 65(3):418-420.
28. Dluzewski A.R., Ling I.T., Rangachari K., Bates P.A., Wilson R.J. A simple method for isolating viable mature parasites of Plasmodium falciparum from cultures. Trans R Soc Trop Med Hyg 1984, 78(5):622-624.
29. Urbán P., Valle-Delgado J.J., Mauro N., Marques J., Manfredi A., Rottmann M., et al. Use of poly(amidoamine) drug conjugates for the delivery of antimalarials to Plasmodium. J Control Release 2014, 177:84-95.
30. 42 fibrillogenesis by glycosaminoglycan structure. FASEB J 2010, 24(11):4250-4261.
31. Adda C.G., Murphy V.J., Sunde M., Waddington L.J., Schloegel J., Talbo G.H., et al. Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils. Mol Biochem Parasitol 2009, 166(2):159-171.
32. Beutler E., Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg 2007, 77(4):779-789.
33. Burgoine K.L., Bancone G., Nosten F. The reality of using primaquine. Malar J 2010, 9(1):376.
34. Chan T.K., Todd D., Tso S.C. Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. BMJ 1976, 2:1227-1229.
35. Xiao L., Yang C., Patterson P.S., Udhayakumar V., Lal A.A. Sulfated polyanions inhibit invasion of erythrocytes by plasmodial merozoites and cytoadherence of endothelial cells to parasitized erythrocytes. Infect Immun 1996, 64(4):1373-1378.
36. Vogt A.M., Pettersson F., Moll K., Jonsson C., Normark J., Ribacke U., et al. Release of sequestered malaria parasites upon injection of a glycosaminoglycan. PLoS Pathog 2006, 2(9):853-863.
37. Kobayashi K., Takano R., Takemae H., Sugi T., Ishiwa A., Gong H., et al. Analyses of interactions between heparin and the apical surface proteins of Plasmodium falciparum. Sci Rep 2013, 3:3178.
38. Zhang Y., Jiang N., Lu H., Hou N., Piao X., Cai P., et al. Proteomic analysis of Plasmodium falciparum schizonts reveals heparin-binding merozoite proteins. J Proteome Res 2013, 12(5):2185-2193.
39. Díaz-Nido J., Wandosell F., Avila J. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002, 23(7):1323-1332.
40. McLaurin J., Fraser P.E. Effect of amino-acid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions. Eur J Biochem 2000, 267(21):6353-6361.
41. Kirk K. Membrane transport in the malaria-infected erythrocyte. Physiol Rev 2001, 81(2):495-537.
42. Goodyer I.D., Pouvelle B., Schneider T.G., Trelka D.P., Taraschi T.F. Characterization of macromolecular transport pathways in malaria-infected erythrocytes. Mol Biochem Parasitol 1997, 87(1):13-28.
43. Staines H.M., Ellory J.C., Kirk K. Perturbation of the pump-leak balance for Na(+) and K(+) in malaria-infected erythrocytes. Am J Physiol Cell Physiol 2001, 280(6):C1576-C1587.
44. Lyon J.A., Carter J.M., Thomas A.W., Chulay J.D. Merozoite surface protein-1 epitopes recognized by antibodies that inhibit Plasmodium falciparum merozoite dispersal. Mol Biochem Parasitol 1997, 90(1):223-234.
45. Bergmann-Leitner E.S., Duncan E.H., Angov E. MSP-1p42-specific antibodies affect growth and development of intra-erythrocytic parasites of Plasmodium falciparum. Malar J 2009, 8:183-194.
46. Rovira-Graells N., Gupta A.P., Planet E., Crowley V.M., Mok S., Ribas de Pouplana L., et al. Transcriptional variation in the malaria parasite Plasmodium falciparum. Genome Res 2012, 22(5):925-938.
47. Urbán P., Estelrich J., Adeva A., Cortés A., Fernàndez-Busquets X. Study of the efficacy of antimalarial drugs delivered inside targeted immunoliposomal nanovectors. Nanoscale Res Lett 2011, 6:620.
48. Leitgeb A.M., Blomqvist K., Cho-Ngwa F., Samje M., Nde P., Titanji V., et al. Low anticoagulant heparin disrupts Plasmodium falciparum rosettes in fresh clinical isolates. Am J Trop Med Hyg 2011, 84(3):390-396.
49. Miura Y., Aoyagi S., Kusada Y., Miyamoto K. The characteristics of anticoagulation by covalently immobilized heparin. J Biomed Mater Res 1980, 14(5):619-630.
50. Osmond R.I.W., Kett W.C., Skett S.E., Coombe D.R. Protein-heparin interactions measured by BIAcore 2000 are affected by the method of heparin immobilization. Anal Biochem 2002, 310(2):199-207.